Mayne Pharma Group (ASX:MYX) said it forecasts growth in its revenue for the fiscal first half ended Dec. 31, 2024, according to a Monday Australian bourse filing.
The firm now expects H1 revenue to be AU$210 million to AU$215 million, reflecting a 12% to 14% rise in the same half-year period the previous year, the filing said.
It also expects to report underlying earnings before interest, taxes, depreciation, and amortization during the period of AU$30 million to AU$32 million, representing an increase of 275% to 300% on the prior year period, driven by continued growth across the women's health portfolio, the filing said.
Its cash and marketable securities came in at AU$124.9 million as of Dec. 31, 2024, a decline of AU$4.6 million compared to the balance as of Oct. 31, 2024.
The firm's shares rose past 16% in early trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.